Plain-English translation of NCT04610866 on ClinicalTrials.gov โ ยท Source last updated ยท How we translate trials
Read our Sickle Cell Disease research guide โPhase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
United States
Phase
Safety & dosing / Early efficacy
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Enrollment target
~15 participants
Started
December 2020
Primary completion
February 2028
Age range
18 Years โ 70 Years
Last updated on clinicaltrials.gov in November 2026.